NO20160182A1 - An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn - Google Patents

An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn Download PDF

Info

Publication number: NO20160182A1
Authority: NO; Norway
Prior art keywords: immunoglobulin; fragment; conjugate; fcrn; binding
Prior art date: 2013-07-12

Application number

NO20160182A

Other languages

English (en)

Inventor

Sung Youb Jung

Se Chang Kwon

Sang Youn Hwang

Jong Soo Lee

Sung Hee Hong

In Young Choi

Original Assignee

Hanmi Pharm Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-12

Filing date

2016-02-03

Publication date

2016-03-02

2016-02-03 Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd

2016-03-02 Publication of NO20160182A1 publication Critical patent/NO20160182A1/en

Links

102000018071 Immunoglobulin Fc Fragments Human genes 0.000 title claims description 200
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 title claims description 200
230000027455 binding Effects 0.000 title claims description 175
108060003951 Immunoglobulin Proteins 0.000 title description 39
102000018358 immunoglobulin Human genes 0.000 title description 39
101150050927 Fcgrt gene Proteins 0.000 title 1
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 162
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 161
108090000765 processed proteins & peptides Proteins 0.000 claims description 73
102000004196 processed proteins & peptides Human genes 0.000 claims description 64
229920001184 polypeptide Polymers 0.000 claims description 63
238000000034 method Methods 0.000 claims description 51
108090000623 proteins and genes Proteins 0.000 claims description 40
235000018102 proteins Nutrition 0.000 claims description 39
102000004169 proteins and genes Human genes 0.000 claims description 39
229920001223 polyethylene glycol Polymers 0.000 claims description 25
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
238000001727 in vivo Methods 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 18
102000002265 Human Growth Hormone Human genes 0.000 claims description 16
108010000521 Human Growth Hormone Proteins 0.000 claims description 16
239000000854 Human Growth Hormone Substances 0.000 claims description 16
239000002202 Polyethylene glycol Substances 0.000 claims description 16
229920000642 polymer Polymers 0.000 claims description 16
102000004877 Insulin Human genes 0.000 claims description 10
108090001061 Insulin Proteins 0.000 claims description 10
229940125396 insulin Drugs 0.000 claims description 10
230000003213 activating effect Effects 0.000 claims description 9
210000004027 cell Anatomy 0.000 claims description 9
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
108010050904 Interferons Proteins 0.000 claims description 8
102000014150 Interferons Human genes 0.000 claims description 8
239000000427 antigen Substances 0.000 claims description 8
102000036639 antigens Human genes 0.000 claims description 8
108091007433 antigens Proteins 0.000 claims description 8
125000003172 aldehyde group Chemical group 0.000 claims description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
102000003951 Erythropoietin Human genes 0.000 claims description 6
108090000394 Erythropoietin Proteins 0.000 claims description 6
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
102000015696 Interleukins Human genes 0.000 claims description 6
108010063738 Interleukins Proteins 0.000 claims description 6
102000013275 Somatomedins Human genes 0.000 claims description 6
229940105423 erythropoietin Drugs 0.000 claims description 6
239000003102 growth factor Substances 0.000 claims description 6
210000002540 macrophage Anatomy 0.000 claims description 6
108010088751 Albumins Proteins 0.000 claims description 5
102000009027 Albumins Human genes 0.000 claims description 5
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 4
108091008324 binding proteins Proteins 0.000 claims description 4
229920002988 biodegradable polymer Polymers 0.000 claims description 4
239000004621 biodegradable polymer Substances 0.000 claims description 4
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 4
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims description 4
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 claims description 3
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 3
102000009840 Angiopoietins Human genes 0.000 claims description 3
108010009906 Angiopoietins Proteins 0.000 claims description 3
102400000068 Angiostatin Human genes 0.000 claims description 3
108010079709 Angiostatins Proteins 0.000 claims description 3
108010064733 Angiotensins Proteins 0.000 claims description 3
102000015427 Angiotensins Human genes 0.000 claims description 3
102100029470 Apolipoprotein E Human genes 0.000 claims description 3
101710095339 Apolipoprotein E Proteins 0.000 claims description 3
102100033367 Appetite-regulating hormone Human genes 0.000 claims description 3
102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 3
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 3
101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 claims description 3
108010074051 C-Reactive Protein Proteins 0.000 claims description 3
102100032752 C-reactive protein Human genes 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 3
229920002101 Chitin Polymers 0.000 claims description 3
101800001982 Cholecystokinin Proteins 0.000 claims description 3
102100025841 Cholecystokinin Human genes 0.000 claims description 3
229940122097 Collagenase inhibitor Drugs 0.000 claims description 3
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 3
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 3
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 3
108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 claims description 3
102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
102000009024 Epidermal Growth Factor Human genes 0.000 claims description 3
101800003838 Epidermal growth factor Proteins 0.000 claims description 3
102000009123 Fibrin Human genes 0.000 claims description 3
108010073385 Fibrin Proteins 0.000 claims description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 3
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 3
102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 3
108700012941 GNRH1 Proteins 0.000 claims description 3
102000004862 Gastrin releasing peptide Human genes 0.000 claims description 3
108090001053 Gastrin releasing peptide Proteins 0.000 claims description 3
108060003199 Glucagon Proteins 0.000 claims description 3
102000003886 Glycoproteins Human genes 0.000 claims description 3
108090000288 Glycoproteins Proteins 0.000 claims description 3
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 3
102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 3
102000001554 Hemoglobins Human genes 0.000 claims description 3
108010054147 Hemoglobins Proteins 0.000 claims description 3
102000007625 Hirudins Human genes 0.000 claims description 3
108010007267 Hirudins Proteins 0.000 claims description 3
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 3
206010020751 Hypersensitivity Diseases 0.000 claims description 3
102000001617 Interferon Receptors Human genes 0.000 claims description 3
108010054267 Interferon Receptors Proteins 0.000 claims description 3
108010063045 Lactoferrin Proteins 0.000 claims description 3
102000010445 Lactoferrin Human genes 0.000 claims description 3
102000016267 Leptin Human genes 0.000 claims description 3
108010092277 Leptin Proteins 0.000 claims description 3
108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 3
108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 3
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 3
206010027476 Metastases Diseases 0.000 claims description 3
108010056852 Myostatin Proteins 0.000 claims description 3
206010028851 Necrosis Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
102400000319 Oxyntomodulin Human genes 0.000 claims description 3
101800001388 Oxyntomodulin Proteins 0.000 claims description 3
102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 3
102000003982 Parathyroid hormone Human genes 0.000 claims description 3
108090000445 Parathyroid hormone Proteins 0.000 claims description 3
102000013566 Plasminogen Human genes 0.000 claims description 3
108010051456 Plasminogen Proteins 0.000 claims description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 3
239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
101800004937 Protein C Proteins 0.000 claims description 3
102000017975 Protein C Human genes 0.000 claims description 3
102000003743 Relaxin Human genes 0.000 claims description 3
108090000103 Relaxin Proteins 0.000 claims description 3
101800001700 Saposin-D Proteins 0.000 claims description 3
102100037505 Secretin Human genes 0.000 claims description 3
108010086019 Secretin Proteins 0.000 claims description 3
101710142969 Somatoliberin Proteins 0.000 claims description 3
102100022831 Somatoliberin Human genes 0.000 claims description 3
108010023197 Streptokinase Proteins 0.000 claims description 3
102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
108010012715 Superoxide dismutase Proteins 0.000 claims description 3
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 3
210000001744 T-lymphocyte Anatomy 0.000 claims description 3
102000000479 TCF Transcription Factors Human genes 0.000 claims description 3
108010016283 TCF Transcription Factors Proteins 0.000 claims description 3
108090000190 Thrombin Proteins 0.000 claims description 3
102000003790 Thrombin receptors Human genes 0.000 claims description 3
102000012607 Thrombomodulin Human genes 0.000 claims description 3
108010079274 Thrombomodulin Proteins 0.000 claims description 3
102000011923 Thyrotropin Human genes 0.000 claims description 3
108010061174 Thyrotropin Proteins 0.000 claims description 3
102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
239000003470 adrenal cortex hormone Substances 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 3
230000007815 allergy Effects 0.000 claims description 3
102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 3
108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 3
210000003719 b-lymphocyte Anatomy 0.000 claims description 3
229960000182 blood factors Drugs 0.000 claims description 3
210000000988 bone and bone Anatomy 0.000 claims description 3
230000008468 bone growth Effects 0.000 claims description 3
229960004015 calcitonin Drugs 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 3
229950008486 carperitide Drugs 0.000 claims description 3
210000000845 cartilage Anatomy 0.000 claims description 3
DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 claims description 3
229940107137 cholecystokinin Drugs 0.000 claims description 3
239000002442 collagenase inhibitor Substances 0.000 claims description 3
210000002808 connective tissue Anatomy 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
102000026898 cytokine binding proteins Human genes 0.000 claims description 3
108091008470 cytokine binding proteins Proteins 0.000 claims description 3
108700032313 elcatonin Proteins 0.000 claims description 3
229960000756 elcatonin Drugs 0.000 claims description 3
229940088598 enzyme Drugs 0.000 claims description 3
229940116977 epidermal growth factor Drugs 0.000 claims description 3
230000008472 epithelial growth Effects 0.000 claims description 3
229950003499 fibrin Drugs 0.000 claims description 3
229940028334 follicle stimulating hormone Drugs 0.000 claims description 3
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 3
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
229960004666 glucagon Drugs 0.000 claims description 3
150000004676 glycans Chemical class 0.000 claims description 3
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
229940006607 hirudin Drugs 0.000 claims description 3
229920002674 hyaluronan Polymers 0.000 claims description 3
229960003160 hyaluronic acid Drugs 0.000 claims description 3
230000002637 immunotoxin Effects 0.000 claims description 3
229940051026 immunotoxin Drugs 0.000 claims description 3
239000002596 immunotoxin Substances 0.000 claims description 3
231100000608 immunotoxin Toxicity 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229940047124 interferons Drugs 0.000 claims description 3
102000002467 interleukin receptors Human genes 0.000 claims description 3
108010093036 interleukin receptors Proteins 0.000 claims description 3
229940047122 interleukins Drugs 0.000 claims description 3
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
229940078795 lactoferrin Drugs 0.000 claims description 3
235000021242 lactoferrin Nutrition 0.000 claims description 3
229940039781 leptin Drugs 0.000 claims description 3
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 3
229940040129 luteinizing hormone Drugs 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
230000017074 necrotic cell death Effects 0.000 claims description 3
239000000199 parathyroid hormone Substances 0.000 claims description 3
229960001319 parathyroid hormone Drugs 0.000 claims description 3
229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 3
229920001451 polypropylene glycol Polymers 0.000 claims description 3
229920001282 polysaccharide Polymers 0.000 claims description 3
239000005017 polysaccharide Substances 0.000 claims description 3
229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 3
229960000856 protein c Drugs 0.000 claims description 3
239000002461 renin inhibitor Substances 0.000 claims description 3
229940086526 renin-inhibitors Drugs 0.000 claims description 3
229960002101 secretin Drugs 0.000 claims description 3
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 3
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 3
230000004936 stimulating effect Effects 0.000 claims description 3
229960005202 streptokinase Drugs 0.000 claims description 3
229960004072 thrombin Drugs 0.000 claims description 3
108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 claims description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
229960005356 urokinase Drugs 0.000 claims description 3
229960005486 vaccine Drugs 0.000 claims description 3
229920002554 vinyl polymer Polymers 0.000 claims description 3
229940053198 antiepileptics succinimide derivative Drugs 0.000 claims description 2
102400000321 Glucagon Human genes 0.000 claims 1
102000023732 binding proteins Human genes 0.000 claims 1
239000000872 buffer Substances 0.000 description 24
230000007935 neutral effect Effects 0.000 description 17
210000002966 serum Anatomy 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 11
230000002378 acidificating effect Effects 0.000 description 10
238000010494 dissociation reaction Methods 0.000 description 10
230000005593 dissociations Effects 0.000 description 10
239000000463 material Substances 0.000 description 10
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 8
102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 8
239000003814 drug Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
238000005349 anion exchange Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000008569 process Effects 0.000 description 6
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 5
239000004365 Protease Substances 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000013543 active substance Substances 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229940079322 interferon Drugs 0.000 description 5
238000005259 measurement Methods 0.000 description 5
GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000004064 recycling Methods 0.000 description 5
102000014914 Carrier Proteins Human genes 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229960001519 exenatide Drugs 0.000 description 4
235000019419 proteases Nutrition 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010011459 Exenatide Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000539 dimer Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
-1 hydroxy succinimidyl Chemical group 0.000 description 3
230000006674 lysosomal degradation Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
125000001151 peptidyl group Chemical group 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000051325 Glucagon Human genes 0.000 description 2
102100029880 Glycodelin Human genes 0.000 description 2
101000585553 Homo sapiens Glycodelin Proteins 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000282887 Suidae Species 0.000 description 2
150000001299 aldehydes Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
238000005341 cation exchange Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000028993 immune response Effects 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
101000913079 Homo sapiens IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
101000866855 Homo sapiens Major histocompatibility complex class I-related gene protein Proteins 0.000 description 1
102100040018 Interferon alpha-2 Human genes 0.000 description 1
108010079944 Interferon-alpha2b Proteins 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
102100031328 Major histocompatibility complex class I-related gene protein Human genes 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
101001053878 Phyllomedusa trinitatis Dermaseptin-TR1 Proteins 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
230000006126 farnesylation Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007500 overflow downdraw method Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000008884 pinocytosis Effects 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20160182A 2013-07-12 2016-02-03 An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn NO20160182A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20130082509		2013-07-12
PCT/KR2014/006328 WO2015005747A1 (ko)	2013-07-12	2014-07-14	FcRn 결합력이 유지되는 면역글로불린 Fc 결합체

Publications (1)

Publication Number	Publication Date
NO20160182A1 true NO20160182A1 (en)	2016-03-02

Family

ID=52280325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20160182A NO20160182A1 (en)	2013-07-12	2016-02-03	An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn

Country Status (21)

Country	Link
US (2)	US20160152684A1 (es)
EP (1)	EP3020732B1 (es)
JP (2)	JP2016525099A (es)
KR (2)	KR101872559B1 (es)
CN (2)	CN105593243A (es)
AR (1)	AR096890A1 (es)
AU (1)	AU2014287879B2 (es)
CA (1)	CA2917838C (es)
DK (1)	DK3020732T3 (es)
EA (1)	EA034297B1 (es)
ES (1)	ES2799326T3 (es)
HU (1)	HU231424B1 (es)
IL (1)	IL243567B (es)
MX (1)	MX376370B (es)
MY (1)	MY180374A (es)
NO (1)	NO20160182A1 (es)
PH (1)	PH12016500111A1 (es)
PT (1)	PT3020732T (es)
TW (1)	TWI693236B (es)
UA (1)	UA119644C2 (es)
WO (1)	WO2015005747A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
MX387560B (es) *	2014-03-31	2025-03-18	Hanmi Pharmaceutical Co Ltd	Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
AR107483A1 (es) *	2016-01-29	2018-05-02	Hanmi Pharm Ind Co Ltd	Conjugado de enzimas terapéuticas
WO2018117613A1 (ko) *	2016-12-19	2018-06-28	한미약품 주식회사	뇌 표적 지속성 단백질 결합체
KR102282240B1 (ko)	2018-12-06	2021-07-28	경상국립대학교산학협력단	지속형 엑센딘-4 및 이의 용도
WO2021010531A1 (ko) *	2019-07-18	2021-01-21	한미약품 주식회사	단백질 결합체의 신규 제조 방법
KR102382593B1 (ko) *	2020-01-29	2022-04-05	고려대학교 산학협력단	pH-감응성 Fc 변이체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6030613A (en) *	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja)	1996-03-18	2008-02-13	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	増大した半減期を有する免疫グロブリン様ドメイン
CN1852732A (zh) *	2002-12-26	2006-10-25	山景医药公司	具有增强的生物学效用的干扰素－β的聚合物缀合物
US20050176108A1 (en) *	2003-03-13	2005-08-11	Young-Min Kim	Physiologically active polypeptide conjugate having prolonged in vivo half-life
RU2352583C2 (ru) *	2003-11-13	2009-04-20	Ханми Фарм. Инд. Ко., Лтд.	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
KR100609434B1 (ko)	2004-12-30	2006-08-03	한국항공우주연구원	트랜스버살 필터
KR100754667B1 (ko) *	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US7625564B2 (en) *	2006-01-27	2009-12-01	Novagen Holding Corporation	Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP2008169195A (ja) *	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20080098216A (ko) *	2007-05-04	2008-11-07	한미약품 주식회사	캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
BRPI0811637B8 (pt) *	2007-05-30	2021-05-25	Genexine Inc	proteínas de fusão da imunoglobulina
JP2009019027A (ja)	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN102112493B (zh) *	2008-07-23	2015-04-01	韩美科学株式会社	包含具有三个官能性末端的非肽基聚合物的多肽复合物
KR20150002894A (ko) *	2010-03-11	2015-01-07	리나트 뉴로사이언스 코프.	ｐＨ 의존성 항원 결합을 갖는 항체
AR081066A1 (es) *	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101337797B1 (ko) *	2010-07-14	2013-12-06	한미사이언스 주식회사	지속형 인간 성장 호르몬 결합체 액상 제제
KR101333958B1 (ko) *	2010-10-20	2013-11-27	주식회사 한독	인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
UA113626C2 (xx) *	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK3878859T5 (da)	2011-06-10	2024-06-10	Hanmi Science Co Ltd	Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) *	2011-06-17	2019-03-29	Hanmi Science Co., Ltd.	Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
CN103611163A (zh) *	2011-09-05	2014-03-05	韩美科学株式会社	一种包含干扰素α-缀合物的抗癌用药物组合物
KR20130049671A (ko) *	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) *	2011-12-30	2019-11-11	한미사이언스 주식회사	면역글로불린 Ｆｃ 단편 유도체
AR094821A1 (es) *	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada

2014
- 2014-07-11 AR ARP140102575A patent/AR096890A1/es active IP Right Grant
- 2014-07-14 CA CA2917838A patent/CA2917838C/en active Active
- 2014-07-14 MX MX2016000344A patent/MX376370B/es active IP Right Grant
- 2014-07-14 TW TW103124093A patent/TWI693236B/zh active
- 2014-07-14 WO PCT/KR2014/006328 patent/WO2015005747A1/ko not_active Ceased
- 2014-07-14 EP EP14822721.8A patent/EP3020732B1/en active Active
- 2014-07-14 HU HUP1600206A patent/HU231424B1/hu unknown
- 2014-07-14 DK DK14822721.8T patent/DK3020732T3/da active
- 2014-07-14 UA UAA201600304A patent/UA119644C2/uk unknown
- 2014-07-14 JP JP2016525294A patent/JP2016525099A/ja active Pending
- 2014-07-14 CN CN201480049342.0A patent/CN105593243A/zh active Pending
- 2014-07-14 MY MYPI2016000028A patent/MY180374A/en unknown
- 2014-07-14 EA EA201690114A patent/EA034297B1/ru unknown
- 2014-07-14 PT PT148227218T patent/PT3020732T/pt unknown
- 2014-07-14 AU AU2014287879A patent/AU2014287879B2/en active Active
- 2014-07-14 ES ES14822721T patent/ES2799326T3/es active Active
- 2014-07-14 KR KR1020140088530A patent/KR101872559B1/ko active Active
- 2014-07-14 US US14/904,543 patent/US20160152684A1/en not_active Abandoned
- 2014-07-14 CN CN202310310247.2A patent/CN116082528A/zh active Pending
2016
- 2016-01-11 IL IL243567A patent/IL243567B/en active IP Right Grant
- 2016-01-12 PH PH12016500111A patent/PH12016500111A1/en unknown
- 2016-02-03 NO NO20160182A patent/NO20160182A1/en unknown
2018
- 2018-06-19 KR KR1020180070435A patent/KR102076718B1/ko active Active
2020
- 2020-04-27 JP JP2020078005A patent/JP6880278B2/ja active Active
2022
- 2022-08-03 US US17/880,358 patent/US20220380437A1/en active Pending

Also Published As

Publication number	Publication date
JP6880278B2 (ja)	2021-06-02
PT3020732T (pt)	2020-06-25
EA034297B1 (ru)	2020-01-27
CA2917838C (en)	2023-06-20
KR20180071241A (ko)	2018-06-27
TWI693236B (zh)	2020-05-11
ES2799326T3 (es)	2020-12-16
JP2016525099A (ja)	2016-08-22
JP2020125337A (ja)	2020-08-20
CA2917838A1 (en)	2015-01-15
AR096890A1 (es)	2016-02-03
EA201690114A1 (ru)	2016-07-29
EP3020732A4 (en)	2016-12-28
PH12016500111A1 (en)	2016-04-18
DK3020732T3 (da)	2020-06-15
CN105593243A (zh)	2016-05-18
EP3020732A1 (en)	2016-05-18
IL243567B (en)	2020-11-30
TW201546093A (zh)	2015-12-16
AU2014287879A1 (en)	2016-02-11
UA119644C2 (uk)	2019-07-25
IL243567A0 (en)	2016-03-31
WO2015005747A1 (ko)	2015-01-15
HU231424B1 (hu)	2023-08-28
US20160152684A1 (en)	2016-06-02
MY180374A (en)	2020-11-28
US20220380437A1 (en)	2022-12-01
HUP1600206A2 (hu)	2016-05-30
EP3020732B1 (en)	2020-03-18
KR101872559B1 (ko)	2018-06-28
NZ716275A (en)	2021-09-24
CN116082528A (zh)	2023-05-09
KR20150008011A (ko)	2015-01-21
MX376370B (es)	2025-03-07
AU2014287879B2 (en)	2020-01-02
MX2016000344A (es)	2016-05-05
KR102076718B1 (ko)	2020-02-12
HK1221957A1 (en)	2017-06-16

Publication	Publication Date	Title
US20220380437A1 (en)	2022-12-01	Immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
EP3020418B1 (en)	2020-02-26	Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
NZ716275B2 (en)	2022-01-06	An Immunoglobulin Fc Conjugate which Maintains Binding Affinity of Immunoglobulin Fc Fragment to FcRn
HK1221957B (en)	2021-01-08	An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
HK40016877A (en)	2020-09-18	Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
HK1223017B (en)	2021-01-08	Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
NZ716251B2 (en)	2021-03-19	Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same